Orbimed Advisors LLC Janux Therapeutics, Inc. Transaction History
Orbimed Advisors LLC
- $4.15 Billion
- Q2 2024
A detailed history of Orbimed Advisors LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 2,979,828 shares of JANX stock, worth $162 Million. This represents 3.01% of its overall portfolio holdings.
Number of Shares
2,979,828
Previous 4,275,553
30.31%
Holding current value
$162 Million
Previous $161 Million
22.46%
% of portfolio
3.01%
Previous 3.62%
Shares
5 transactions
Others Institutions Holding JANX
# of Institutions
160Shares Held
37.2MCall Options Held
70.4KPut Options Held
101K-
Ra Capital Management, L.P. Boston, MA9.17MShares$499 Million5.79% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$127 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.33MShares$127 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$98 Million0.04% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY1.56MShares$85.1 Million2.65% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.27B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...